# Efficacy and Safety of T+A+RAD in HCC

> **NCT05396937** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 42 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **RADIATION:** Multifocal Stereotactic Radiotherapy
- **DRUG:** Atezolizumab Injection [Tecentriq]
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT05396937
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-12
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2022-05-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05396937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05396937, "Efficacy and Safety of T+A+RAD in HCC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05396937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*